Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Mlq Ai

Published November 16, 2026 · Updated November 17, 2026

Helus Pharma's psychedelic depression drug meets its Phase 3 goal but faces safety questions

Read the full story at Mlq Ai

Helus Pharma said its psychedelic drug HLP003 met the main goal of the Phase 3 APPROACH study in adults with major depression whose symptoms.

Surfaced by 2 Google Alerts

  • Psychedelics
  • Psychedelic press release